NRBO Research and Charts

NRBO - NeuroBo Pharmaceuticals Inc (Healthcare: Biotechnology)

Projected Earnings Date: 0000-02-29 (Delayed quote data 2026-02-10)

Last 1.70	Change ⇓ -0.03 (-1.73%)	Volume 190,383
	Open 1.83	High 1.83	Low 1.63

8EMA (Daily) 2.14	40EMA (Daily) 4.23	50EMA (Daily) 4.26	STO (Daily) 2.957	MACD Hist (Daily) 0.104
8EMA (Weekly) 3.583	40EMA (Weekly) 2.94	50EMA (Weekly) 2.77	STO (Weekly) 14.064	MACD Hist (Weekly) -0.912


Company Profile
NeuroBo Pharmaceuticals Inc is a clinical-stage biotechnology company focused on developing and commercializing multi-modal disease-modifying therapies for viral, neuropathic, and neurodegenerative diseases, has a current portfolio of four drug candidates. The company's acquired ANA001 candidate is a proprietary oral niclosamide formulation in development as a treatment for patients with moderate to severe COVID-19. ANA001 is being studied in a 60-subject Phase 2/3 clinical trial conducted at up to 20 clinical sites in the USA. The company's NB-01 candidate has been shown in a Phase 2 study to significantly reduce pain symptoms associated with painful diabetic neuropathy (PDN), with a superior safety profile when compared to currently available treatments.

Disclaimer: All information provided is for informational purposes only and not intended for trading purposes or advice. The quotes and charts are not real time and have delays of at least 20 minutes. Data accuracy cannot be guaranteed as errors will occur. Please do not rely on the above information to make your stock/option trades. Neither OptionChance.com nor any of independent data providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein.